Literature DB >> 33772006

TDP-43 and PINK1 mediate CHCHD10S59L mutation-induced defects in Drosophila and in vitro.

Minwoo Baek1, Yun-Jeong Choe1, Sylvie Bannwarth2, JiHye Kim1, Swati Maitra1, Gerald W Dorn3, J Paul Taylor4, Veronique Paquis-Flucklinger2, Nam Chul Kim5.   

Abstract

Mutations in coiled-coil-helix-coiled-coil-helix domain containing 10 (CHCHD10) can cause amyotrophic lateral sclerosis and frontotemporal dementia (ALS-FTD). However, the underlying mechanisms are unclear. Here, we generate CHCH10S59L-mutant Drosophila melanogaster and HeLa cell lines to model CHCHD10-associated ALS-FTD. The CHCHD10S59L mutation results in cell toxicity in several tissues and mitochondrial defects. CHCHD10S59L independently affects the TDP-43 and PINK1 pathways. CHCHD10S59L expression increases TDP-43 insolubility and mitochondrial translocation. Blocking TDP-43 mitochondrial translocation with a peptide inhibitor reduced CHCHD10S59L-mediated toxicity. While genetic and pharmacological modulation of PINK1 expression and activity of its substrates rescues and mitigates the CHCHD10S59L-induced phenotypes and mitochondrial defects, respectively, in both Drosophila and HeLa cells. Our findings suggest that CHCHD10S59L-induced TDP-43 mitochondrial translocation and chronic activation of PINK1-mediated pathways result in dominant toxicity, providing a mechanistic insight into the CHCHD10 mutations associated with ALS-FTD.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33772006      PMCID: PMC7997989          DOI: 10.1038/s41467-021-22145-9

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  56 in total

Review 1.  TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia.

Authors:  Ian Ra Mackenzie; Rosa Rademakers; Manuela Neumann
Journal:  Lancet Neurol       Date:  2010-10       Impact factor: 44.182

2.  Ubiquitin is phosphorylated by PINK1 to activate parkin.

Authors:  Fumika Koyano; Kei Okatsu; Hidetaka Kosako; Yasushi Tamura; Etsu Go; Mayumi Kimura; Yoko Kimura; Hikaru Tsuchiya; Hidehito Yoshihara; Takatsugu Hirokawa; Toshiya Endo; Edward A Fon; Jean-François Trempe; Yasushi Saeki; Keiji Tanaka; Noriyuki Matsuda
Journal:  Nature       Date:  2014-06-04       Impact factor: 49.962

3.  MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A.

Authors:  Agostinho G Rocha; Antonietta Franco; Andrzej M Krezel; Jeanne M Rumsey; Justin M Alberti; William C Knight; Nikolaos Biris; Emmanouil Zacharioudakis; James W Janetka; Robert H Baloh; Richard N Kitsis; Daria Mochly-Rosen; R Reid Townsend; Evripidis Gavathiotis; Gerald W Dorn
Journal:  Science       Date:  2018-04-20       Impact factor: 47.728

4.  VCP is essential for mitochondrial quality control by PINK1/Parkin and this function is impaired by VCP mutations.

Authors:  Nam Chul Kim; Emilie Tresse; Regina-Maria Kolaitis; Amandine Molliex; Ruth E Thomas; Nael H Alami; Bo Wang; Aashish Joshi; Rebecca B Smith; Gillian P Ritson; Brett J Winborn; Jennifer Moore; Joo-Yong Lee; Tso-Pang Yao; Leo Pallanck; Mondira Kundu; J Paul Taylor
Journal:  Neuron       Date:  2013-03-14       Impact factor: 17.173

Review 5.  The fluorescent protein palette: tools for cellular imaging.

Authors:  Richard N Day; Michael W Davidson
Journal:  Chem Soc Rev       Date:  2009-08-04       Impact factor: 54.564

6.  Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice.

Authors:  Marina Mattiazzi; Marilena D'Aurelio; Carl D Gajewski; Katherine Martushova; Mahmoud Kiaei; M Flint Beal; Giovanni Manfredi
Journal:  J Biol Chem       Date:  2002-06-05       Impact factor: 5.157

7.  Mutation analysis of CHCHD10 in different neurodegenerative diseases.

Authors:  Ming Zhang; Zhengrui Xi; Lorne Zinman; Amalia C Bruni; Raffaele G Maletta; Sabrina A M Curcio; Innocenzo Rainero; Elisa Rubino; Lorenzo Pinessi; Benedetta Nacmias; Sandro Sorbi; Daniela Galimberti; Anthony E Lang; Susan Fox; Ezequiel I Surace; Mahdi Ghani; Jing Guo; Christine Sato; Danielle Moreno; Yan Liang; Julia Keith; Bryan J Traynor; Peter St George-Hyslop; Ekaterina Rogaeva
Journal:  Brain       Date:  2015-03-31       Impact factor: 13.501

8.  A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement.

Authors:  Sylvie Bannwarth; Samira Ait-El-Mkadem; Annabelle Chaussenot; Emmanuelle C Genin; Sandra Lacas-Gervais; Konstantina Fragaki; Laetitia Berg-Alonso; Yusuke Kageyama; Valérie Serre; David G Moore; Annie Verschueren; Cécile Rouzier; Isabelle Le Ber; Gaëlle Augé; Charlotte Cochaud; Françoise Lespinasse; Karine N'Guyen; Anne de Septenville; Alexis Brice; Patrick Yu-Wai-Man; Hiromi Sesaki; Jean Pouget; Véronique Paquis-Flucklinger
Journal:  Brain       Date:  2014-06-16       Impact factor: 13.501

9.  The itinerary of autophagosomes: from peripheral formation to kiss-and-run fusion with lysosomes.

Authors:  Luca Jahreiss; Fiona M Menzies; David C Rubinsztein
Journal:  Traffic       Date:  2008-01-07       Impact factor: 6.215

10.  CHCHD10 mutations promote loss of mitochondrial cristae junctions with impaired mitochondrial genome maintenance and inhibition of apoptosis.

Authors:  Emmanuelle C Genin; Morgane Plutino; Sylvie Bannwarth; Elodie Villa; Eugenia Cisneros-Barroso; Madhuparna Roy; Bernardo Ortega-Vila; Konstantina Fragaki; Françoise Lespinasse; Estefania Pinero-Martos; Gaëlle Augé; David Moore; Florence Burté; Sandra Lacas-Gervais; Yusuke Kageyama; Kie Itoh; Patrick Yu-Wai-Man; Hiromi Sesaki; Jean-Ehrland Ricci; Cristofol Vives-Bauza; Véronique Paquis-Flucklinger
Journal:  EMBO Mol Med       Date:  2016-01-01       Impact factor: 12.137

View more
  6 in total

1.  Modulation of synaptic plasticity, motor unit physiology, and TDP-43 pathology by CHCHD10.

Authors:  Tian Liu; Jung-A A Woo; Mohammed Zaheen Bukhari; Xinming Wang; Yan Yan; Sara Cazzaro Buosi; Aizara Ermekbaeva; Apoorva Sista; Peter Kotsiviras; Patrick LePochat; Ann Chacko; Xingyu Zhao; David E Kang
Journal:  Acta Neuropathol Commun       Date:  2022-07-04       Impact factor: 7.578

Review 2.  CHCHD2 and CHCHD10: Future therapeutic targets in cognitive disorder and motor neuron disorder.

Authors:  Tianlin Jiang; Yanli Wang; Xiaohong Wang; Jun Xu
Journal:  Front Neurosci       Date:  2022-08-18       Impact factor: 5.152

3.  Inter-organellar and systemic responses to impaired mitochondrial matrix protein import in skeletal muscle.

Authors:  Nirajan Neupane; Jayasimman Rajendran; Jouni Kvist; Sandra Harjuhaahto; Bowen Hu; Veijo Kinnunen; Yang Yang; Anni I Nieminen; Henna Tyynismaa
Journal:  Commun Biol       Date:  2022-10-05

Review 4.  Protein condensation diseases: therapeutic opportunities.

Authors:  Michele Vendruscolo; Monika Fuxreiter
Journal:  Nat Commun       Date:  2022-09-22       Impact factor: 17.694

5.  PINK1 Alleviates Cognitive Impairments via Attenuating Pathological Tau Aggregation in a Mouse Model of Tauopathy.

Authors:  Xing Jun Jiang; Yan Qing Wu; Rong Ma; Yan Min Chang; Lu Lu Li; Jia Hui Zhu; Gong Ping Liu; Gang Li
Journal:  Front Cell Dev Biol       Date:  2022-01-04

Review 6.  Predicting Mitochondrial Dynamic Behavior in Genetically Defined Neurodegenerative Diseases.

Authors:  Gerald W Dorn; Xiawei Dang
Journal:  Cells       Date:  2022-03-19       Impact factor: 7.666

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.